Cellectar Biosciences Inc  

(Public, NASDAQ:CLRB)   Watch this stock  
Find more results for Simon Pedder�
2.59
+0.03 (1.17%)
Nov 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.58 - 2.59
52 week 1.76 - 9.20
Open 2.59
Vol / Avg. 603.00/22,740.00
Mkt cap 19.44M
P/E     -
Div/yield     -
EPS -3.23
Shares 7.56M
Beta -0.10
Inst. own 51%
Nov 11, 2014
Q3 2014 Cellectar Biosciences Inc Earnings Call
Nov 11, 2014
Q3 2014 Cellectar Biosciences Inc Earnings Release
Nov 5, 2014
Cellectar Biosciences Inc at EBD Group BIO-Europe Conference
Sep 11, 2014
Cellectar Biosciences Inc at Aegis Capital Corp Healthcare & Technology Conference
Sep 9, 2014
Cellectar Biosciences Inc at Rodman & Renshaw Global Investment Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -18.77% -117.88%
Return on average equity -38.24% -181.86%
Employees 24 -
CDP Score - -

Address

3301 Agriculture Dr
MADISON, WI 53716-4133
United States - Map
+1-617-2441616 (Phone)
+1-608-4418121 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc. is engaged in developing agents to detect, treat and monitor a broad spectrum of cancers. Utilizing a phospholipid ether (PLE) platform technology as a targeted delivery and retention vehicle, its compounds are designed to be selectively taken up and retained in both cancer cells and cancer stem cells. The Company�s portfolio consists of PET imaging agents, optical imaging agents and therapeutic agents. The Company's I-124-CLR1404 is a small-molecule, broad-spectrum, cancer-targeted PET imaging agent. Its I-131-CLR1404 is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells. Its CLR1502 is a preclinical, cancer-targeted, non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging.

Officers and directors

Stephen Anthony Hill M.D. Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
Simon Pedder Ph.D. President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Chad J. Kolean Chief Financial Officer, Vice President - Finance, Treasurer
Bio & Compensation  - Reuters
Jamey P. Weichert Ph.D. Chief Scientific Officer, Director
Age: 57
Bio & Compensation  - Reuters
Kathryn M. McNeil Vice President - Investor Relations, Public Relations and Corporate Communications
Bio & Compensation  - Reuters
Cameron Szakacs Ph.D. Vice President - Clinical Development
Age: 51
Bio & Compensation  - Reuters
J. Patrick Genn Vice President - Business Development
Age: 56
Bio & Compensation  - Reuters
Kevin Kozak M.D., Ph.D. Chief Medical Officer
Bio & Compensation  - Reuters
Paul L. Berns Independent Director
Age: 47
Bio & Compensation  - Reuters
John P. Neis Independent Director
Age: 57
Bio & Compensation  - Reuters